Tresiba Flextouch U-200 (Insulin Degludec) — Medicare Part D spending
Novo Nordisk · Rank #48 by total Part D spend · CMS data year 2023
Medicare Part D spent $1,047,670,731 on Tresiba Flextouch U-200 (Insulin Degludec) in 2023, the #48 drug by total Part D spending out of 3,598 drugs. That worked out to about $71.71 per dosage unit, $1,238 per claim and $5,316 per beneficiary, across 846,009 claims for 197,096 beneficiaries. Average spending per dosage unit rose +0.9% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Tresiba Flextouch U-200 (Insulin Degludec) spending at a glance (2023)
| Metric | Tresiba Flextouch U-200 (Insulin Degludec) |
|---|---|
| Total Part D spending (2023) | $1,047,670,731 |
| Total spending (2022) | $1,002,093,649 |
| Year-over-year change in total spending | +4.5% |
| Average spending per dosage unit (2023) | $71.71 |
| Change in spend per dosage unit (YoY) | +0.9% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +1.2% |
| Average spending per claim (2023) | $1,238 |
| Average spending per beneficiary (2023) | $5,316 |
| Total claims (2023) | 846,009 |
| Beneficiaries (2023) | 197,096 |
| Total dosage units (2023) | 14,610,581 |
| Manufacturer(s) | Novo Nordisk |
| National rank by total spend (of 3,598 drugs) | #48 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $1,002,093,649 | $1,047,670,731 | +4.5% |
| Avg spend per dosage unit | $71.06 | $71.71 | +0.9% |
| Avg spend per claim | $1,214 | $1,238 | — |
| Avg spend per beneficiary | $5,383 | $5,316 | — |
| Total claims | 825,325 | 846,009 | — |
| Beneficiaries | 186,155 | 197,096 | — |
How Tresiba Flextouch U-200 compares with nearby drugs
Drugs with total Part D spending closest to Tresiba Flextouch U-200 (Insulin Degludec):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Tresiba Flextouch U-200 (Insulin Degludec) (this drug, #48) | $1,047,670,731 | $71.71 | +0.9% |
| Dupixent Pen (Dupilumab) (#46) | $1,081,417,351 | $951.72 | +7.5% |
| Erleada (Apalutamide) (#47) | $1,057,789,083 | $156.58 | +32.1% |
| Levemir Flexpen (Insulin Detemir) (#49) | $1,025,556,477 | $32.59 | — |
| Opsumit (Macitentan) (#50) | $1,018,837,123 | $424.66 | +8.3% |
| Victoza 3-Pak (Liraglutide) (#51) | $1,004,635,145 | $126.95 | +4.5% |
Frequently asked questions
How much does Medicare Part D spend on Tresiba Flextouch U-200?
Medicare Part D spent $1,047,670,731 on Tresiba Flextouch U-200 (Insulin Degludec) in 2023 (the latest CMS data year), across 846,009 claims for 197,096 beneficiaries. That ranks #48 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Tresiba Flextouch U-200?
In 2023, the weighted average Medicare Part D spending per dosage unit for Tresiba Flextouch U-200 (Insulin Degludec) was $71.71. Compared with 2022 it rose +0.9%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Tresiba Flextouch U-200?
CMS attributes Tresiba Flextouch U-200 (Insulin Degludec) to Novo Nordisk in the 2023 Part D spending file. Average spending per claim was $1,238 and per beneficiary $5,316.
Is the Tresiba Flextouch U-200 figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20